Literature DB >> 20092694

The clinical course of calpainopathy (LGMD2A) and dysferlinopathy (LGMD2B).

C Angelini1, L Nardetto, C Borsato, R Padoan, M Fanin, A C Nascimbeni, E Tasca.   

Abstract

OBJECTIVE: Autosomal recessive limb girdle muscular dystrophies (LGMD type 2) are a clinically and genetically heterogeneous group of disorders, characterized by progressive involvement and wasting of limb girdle muscles. In order to describe the peculiar clinical features of LGMD2A (calpainopathy) and LGMD2B (dysferlinopathy), the most frequent forms of LGMD in European countries, we analysed and compared the phenotype and the clinical course in two relatively large groups of these patients.
METHODS: We selected 22 patients with a molecular diagnosis of LGMD2A and 21 patients with LGMD2B and reported their clinical data collected from both clinical history and during periodical neuromuscular examinations: age and distribution of muscle involvement at onset, clinical functional score by the use of ten-point modified scale of Gardner-Medwin and Walton at onset and at last clinical examination, and the rate of disease progression.
RESULTS: LGMD2A group included patients with different ages at onset (early-onset or late-onset), different phenotypes (upper girdle in Erb LGMD or lower girdle in Leyden-Moebius LGMD) and different disease progressions (rapid or slow course). LGMD2B patients differed for pattern of muscle involvement at onset (distal in Miyoshi dystrophy or proximal in Leyden-Moebius LGMD) but they had a rather homogeneous age at onset (in the second/third decade) and rate of disease progression. DISCUSSION: Our data show that besides the clinical differences within each group of patients, the two forms of LGMD present distinctive clinical features. The various phenotypes and courses can be attributed to specific pathogenetic mechanisms and might suggest differential therapeutic strategies.

Entities:  

Mesh:

Year:  2010        PMID: 20092694     DOI: 10.1179/174313209X380847

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  23 in total

1.  Identification of two novel SMCHD1 sequence variants in families with FSHD-like muscular dystrophy.

Authors:  Jincy Winston; Laura Duerden; Matthew Mort; Ian M Frayling; Mark T Rogers; Meena Upadhyaya
Journal:  Eur J Hum Genet       Date:  2014-04-23       Impact factor: 4.246

2.  Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity.

Authors:  Sabrina Sacconi; Pilar Camaño; Jessica C de Greef; Richard J L F Lemmers; Leonardo Salviati; Pascal Boileau; Adolfo Lopez de Munain Arregui; Silvère M van der Maarel; Claude Desnuelle
Journal:  J Med Genet       Date:  2011-10-07       Impact factor: 6.318

3.  Gene Correction of LGMD2A Patient-Specific iPSCs for the Development of Targeted Autologous Cell Therapy.

Authors:  Sridhar Selvaraj; Neha R Dhoke; James Kiley; Alba Judith Mateos-Aierdi; Sudheer Tungtur; Ricardo Mondragon-Gonzalez; Grace Killeen; Vanessa K P Oliveira; Adolfo López de Munain; Rita C R Perlingeiro
Journal:  Mol Ther       Date:  2019-08-28       Impact factor: 11.454

4.  Novel Missense CAPN3 Mutation Responsible for Adult-Onset Limb Girdle Muscular Dystrophy with Calves Hypertrophy.

Authors:  Sabrine Rekik; Salma Sakka; Sawssan Ben Romdhan; Nouha Farhat; Yasmine Baba Amer; Leila Lehkim; François Jérôme Authier; Chokri Mhiri
Journal:  J Mol Neurosci       Date:  2019-08-13       Impact factor: 3.444

5.  The 2022 On-site Padua Days on Muscle and Mobility Medicine hosts the University of Florida Institute of Myology and the Wellstone Center, March 30 - April 3, 2022 at the University of Padua and Thermae of Euganean Hills, Padua, Italy: The collection of abstracts.

Authors:  H Lee Sweeney; Stefano Masiero; Ugo Carraro
Journal:  Eur J Transl Myol       Date:  2022-03-10

6.  Muscular dystrophy with marked Dysferlin deficiency is consistently caused by primary dysferlin gene mutations.

Authors:  Mafalda Cacciottolo; Gelsomina Numitone; Stefania Aurino; Imma Rosaria Caserta; Marina Fanin; Luisa Politano; Carlo Minetti; Enzo Ricci; Giulio Piluso; Corrado Angelini; Vincenzo Nigro
Journal:  Eur J Hum Genet       Date:  2011-04-27       Impact factor: 4.246

7.  Dysferlinopathy course and sportive activity: clues for possible treatment.

Authors:  C Angelini; E Peterle; A Gaiani; L Bortolussi; C Borsato
Journal:  Acta Myol       Date:  2011-10

8.  Calpain 3 is important for muscle regeneration: evidence from patients with limb girdle muscular dystrophies.

Authors:  Simon Hauerslev; Marie-Louise Sveen; Morten Duno; Corrado Angelini; John Vissing; Thomas O Krag
Journal:  BMC Musculoskelet Disord       Date:  2012-03-23       Impact factor: 2.362

9.  Genetic silencing of Nrf2 enhances X-ROS in dysferlin-deficient muscle.

Authors:  Ponvijay Kombairaju; Jaclyn P Kerr; Joseph A Roche; Stephen J P Pratt; Richard M Lovering; Thomas E Sussan; Jung-Hyun Kim; Guoli Shi; Shyam Biswal; Christopher W Ward
Journal:  Front Physiol       Date:  2014-02-19       Impact factor: 4.566

Review 10.  A Journey with LGMD: From Protein Abnormalities to Patient Impact.

Authors:  Dimitra G Georganopoulou; Vasilis G Moisiadis; Firhan A Malik; Ali Mohajer; Tanya M Dashevsky; Shirley T Wuu; Chih-Kao Hu
Journal:  Protein J       Date:  2021-06-10       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.